

Global Chronic Pulmonary Hypertension Drug Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G987B2753E04EN.html>

Date: March 2023

Pages: 109

Price: US\$ 4,480.00 (Single User License)

ID: G987B2753E04EN

Abstracts

The global Chronic Pulmonary Hypertension Drug market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.

This report studies the global Chronic Pulmonary Hypertension Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Chronic Pulmonary Hypertension Drug, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chronic Pulmonary Hypertension Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Chronic Pulmonary Hypertension Drug total market, 2018-2029, (USD Million)

Global Chronic Pulmonary Hypertension Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Chronic Pulmonary Hypertension Drug total market, key domestic companies and share, (USD Million)

Global Chronic Pulmonary Hypertension Drug revenue by player and market share
2018-2023, (USD Million)

Global Chronic Pulmonary Hypertension Drug total market by Type, CAGR, 2018-2029,
(USD Million)

Global Chronic Pulmonary Hypertension Drug total market by Application, CAGR,
2018-2029, (USD Million)

This reports profiles major players in the global Chronic Pulmonary Hypertension Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmmed and Altavant Sciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chronic Pulmonary Hypertension Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Chronic Pulmonary Hypertension Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Chronic Pulmonary Hypertension Drug Market, Segmentation by Type

Oral

Intravenous/Subcutaneous

Inhalational

Global Chronic Pulmonary Hypertension Drug Market, Segmentation by Application

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Companies Profiled:

Bayer

Attgeno

Cereno Scientific

Bial - Portela C S.A

Liquidia Technologies

Bellerophon Therapeutics

AbbVie Therapeutics

Insmed

Altavant Sciences

Lupin

Sun Pharmaceutical

Teva

Key Questions Answered

1. How big is the global Chronic Pulmonary Hypertension Drug market?
2. What is the demand of the global Chronic Pulmonary Hypertension Drug market?
3. What is the year over year growth of the global Chronic Pulmonary Hypertension Drug market?
4. What is the total value of the global Chronic Pulmonary Hypertension Drug market?
5. Who are the major players in the global Chronic Pulmonary Hypertension Drug market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Chronic Pulmonary Hypertension Drug Introduction
- 1.2 World Chronic Pulmonary Hypertension Drug Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Chronic Pulmonary Hypertension Drug Total Market by Region (by Headquarter Location)
 - 1.3.1 World Chronic Pulmonary Hypertension Drug Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.3 China Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.4 Europe Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.5 Japan Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.6 South Korea Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.7 ASEAN Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
 - 1.3.8 India Chronic Pulmonary Hypertension Drug Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Chronic Pulmonary Hypertension Drug Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Chronic Pulmonary Hypertension Drug Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)
- 2.2 World Chronic Pulmonary Hypertension Drug Consumption Value by Region
 - 2.2.1 World Chronic Pulmonary Hypertension Drug Consumption Value by Region (2018-2023)
 - 2.2.2 World Chronic Pulmonary Hypertension Drug Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)
- 2.4 China Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)
- 2.5 Europe Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)
- 2.6 Japan Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)

2.7 South Korea Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)

2.8 ASEAN Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)

2.9 India Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029)

3 WORLD CHRONIC PULMONARY HYPERTENSION DRUG COMPANIES COMPETITIVE ANALYSIS

3.1 World Chronic Pulmonary Hypertension Drug Revenue by Player (2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Chronic Pulmonary Hypertension Drug Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Chronic Pulmonary Hypertension Drug in 2022

3.2.3 Global Concentration Ratios (CR8) for Chronic Pulmonary Hypertension Drug in 2022

3.3 Chronic Pulmonary Hypertension Drug Company Evaluation Quadrant

3.4 Chronic Pulmonary Hypertension Drug Market: Overall Company Footprint Analysis

3.4.1 Chronic Pulmonary Hypertension Drug Market: Region Footprint

3.4.2 Chronic Pulmonary Hypertension Drug Market: Company Product Type Footprint

3.4.3 Chronic Pulmonary Hypertension Drug Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Chronic Pulmonary Hypertension Drug Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Chronic Pulmonary Hypertension Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: Chronic Pulmonary Hypertension Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: Chronic Pulmonary Hypertension Drug Consumption Value Comparison

4.2.1 United States VS China: Chronic Pulmonary Hypertension Drug Consumption

Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Chronic Pulmonary Hypertension Drug Consumption

Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based Chronic Pulmonary Hypertension Drug Companies and Market Share, 2018-2023

4.3.1 United States Based Chronic Pulmonary Hypertension Drug Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023)

4.4 China Based Companies Chronic Pulmonary Hypertension Drug Revenue and Market Share, 2018-2023

4.4.1 China Based Chronic Pulmonary Hypertension Drug Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023)

4.5 Rest of World Based Chronic Pulmonary Hypertension Drug Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Chronic Pulmonary Hypertension Drug Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Chronic Pulmonary Hypertension Drug Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Oral

5.2.2 Intravenous/Subcutaneous

5.2.3 Inhalational

5.3 Market Segment by Type

5.3.1 World Chronic Pulmonary Hypertension Drug Market Size by Type (2018-2023)

5.3.2 World Chronic Pulmonary Hypertension Drug Market Size by Type (2024-2029)

5.3.3 World Chronic Pulmonary Hypertension Drug Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Chronic Pulmonary Hypertension Drug Market Size Overview by Application:

2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Hospital Pharmacy

6.2.2 Retail Pharmacy

6.2.3 Online Pharmacy

6.3 Market Segment by Application

6.3.1 World Chronic Pulmonary Hypertension Drug Market Size by Application (2018-2023)

6.3.2 World Chronic Pulmonary Hypertension Drug Market Size by Application (2024-2029)

6.3.3 World Chronic Pulmonary Hypertension Drug Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Bayer

7.1.1 Bayer Details

7.1.2 Bayer Major Business

7.1.3 Bayer Chronic Pulmonary Hypertension Drug Product and Services

7.1.4 Bayer Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Bayer Recent Developments/Updates

7.1.6 Bayer Competitive Strengths & Weaknesses

7.2 Attgeno

7.2.1 Attgeno Details

7.2.2 Attgeno Major Business

7.2.3 Attgeno Chronic Pulmonary Hypertension Drug Product and Services

7.2.4 Attgeno Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Attgeno Recent Developments/Updates

7.2.6 Attgeno Competitive Strengths & Weaknesses

7.3 Cereno Scientific

7.3.1 Cereno Scientific Details

7.3.2 Cereno Scientific Major Business

7.3.3 Cereno Scientific Chronic Pulmonary Hypertension Drug Product and Services

7.3.4 Cereno Scientific Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Cereno Scientific Recent Developments/Updates

7.3.6 Cereno Scientific Competitive Strengths & Weaknesses

7.4 Bial - Portela C S.A

7.4.1 Bial - Portela C S.A Details

7.4.2 Bial - Portela C S.A Major Business

7.4.3 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Product and Services

7.4.4 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Bial - Portela C S.A Recent Developments/Updates

7.4.6 Bial - Portela C S.A Competitive Strengths & Weaknesses

7.5 Liquidia Technologies

7.5.1 Liquidia Technologies Details

7.5.2 Liquidia Technologies Major Business

7.5.3 Liquidia Technologies Chronic Pulmonary Hypertension Drug Product and Services

7.5.4 Liquidia Technologies Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Liquidia Technologies Recent Developments/Updates

7.5.6 Liquidia Technologies Competitive Strengths & Weaknesses

7.6 Bellerophon Therapeutics

7.6.1 Bellerophon Therapeutics Details

7.6.2 Bellerophon Therapeutics Major Business

7.6.3 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Product and Services

7.6.4 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Bellerophon Therapeutics Recent Developments/Updates

7.6.6 Bellerophon Therapeutics Competitive Strengths & Weaknesses

7.7 AbbVie Therapeutics

7.7.1 AbbVie Therapeutics Details

7.7.2 AbbVie Therapeutics Major Business

7.7.3 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Product and Services

7.7.4 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 AbbVie Therapeutics Recent Developments/Updates

7.7.6 AbbVie Therapeutics Competitive Strengths & Weaknesses

7.8 Insmed

7.8.1 Insmed Details

7.8.2 Insmed Major Business

7.8.3 Insmed Chronic Pulmonary Hypertension Drug Product and Services

7.8.4 Insmed Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 Insmed Recent Developments/Updates

7.8.6 Insmed Competitive Strengths & Weaknesses

7.9 Altavant Sciences

7.9.1 Altavant Sciences Details

7.9.2 Altavant Sciences Major Business

7.9.3 Altavant Sciences Chronic Pulmonary Hypertension Drug Product and Services

7.9.4 Altavant Sciences Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.9.5 Altavant Sciences Recent Developments/Updates

7.9.6 Altavant Sciences Competitive Strengths & Weaknesses

7.10 Lupin

7.10.1 Lupin Details

7.10.2 Lupin Major Business

7.10.3 Lupin Chronic Pulmonary Hypertension Drug Product and Services

7.10.4 Lupin Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.10.5 Lupin Recent Developments/Updates

7.10.6 Lupin Competitive Strengths & Weaknesses

7.11 Sun Pharmaceutical

7.11.1 Sun Pharmaceutical Details

7.11.2 Sun Pharmaceutical Major Business

7.11.3 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Product and Services

7.11.4 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.11.5 Sun Pharmaceutical Recent Developments/Updates

7.11.6 Sun Pharmaceutical Competitive Strengths & Weaknesses

7.12 Teva

7.12.1 Teva Details

7.12.2 Teva Major Business

7.12.3 Teva Chronic Pulmonary Hypertension Drug Product and Services

7.12.4 Teva Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023)

7.12.5 Teva Recent Developments/Updates

7.12.6 Teva Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Chronic Pulmonary Hypertension Drug Industry Chain

8.2 Chronic Pulmonary Hypertension Drug Upstream Analysis

8.3 Chronic Pulmonary Hypertension Drug Midstream Analysis

8.4 Chronic Pulmonary Hypertension Drug Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Chronic Pulmonary Hypertension Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Chronic Pulmonary Hypertension Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Chronic Pulmonary Hypertension Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Chronic Pulmonary Hypertension Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Chronic Pulmonary Hypertension Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Chronic Pulmonary Hypertension Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Chronic Pulmonary Hypertension Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Chronic Pulmonary Hypertension Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Chronic Pulmonary Hypertension Drug Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Chronic Pulmonary Hypertension Drug Players in 2022

Table 12. World Chronic Pulmonary Hypertension Drug Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Chronic Pulmonary Hypertension Drug Company Evaluation Quadrant

Table 14. Head Office of Key Chronic Pulmonary Hypertension Drug Player

Table 15. Chronic Pulmonary Hypertension Drug Market: Company Product Type Footprint

Table 16. Chronic Pulmonary Hypertension Drug Market: Company Product Application Footprint

Table 17. Chronic Pulmonary Hypertension Drug Mergers & Acquisitions Activity

Table 18. United States VS China Chronic Pulmonary Hypertension Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Chronic Pulmonary Hypertension Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Chronic Pulmonary Hypertension Drug Companies,

Headquarters (States, Country)

Table 21. United States Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Chronic Pulmonary Hypertension Drug Revenue Market Share (2018-2023)

Table 23. China Based Chronic Pulmonary Hypertension Drug Companies, Headquarters (Province, Country)

Table 24. China Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Chronic Pulmonary Hypertension Drug Revenue Market Share (2018-2023)

Table 26. Rest of World Based Chronic Pulmonary Hypertension Drug Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Chronic Pulmonary Hypertension Drug Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Chronic Pulmonary Hypertension Drug Revenue Market Share (2018-2023)

Table 29. World Chronic Pulmonary Hypertension Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Chronic Pulmonary Hypertension Drug Market Size by Type (2018-2023) & (USD Million)

Table 31. World Chronic Pulmonary Hypertension Drug Market Size by Type (2024-2029) & (USD Million)

Table 32. World Chronic Pulmonary Hypertension Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Chronic Pulmonary Hypertension Drug Market Size by Application (2018-2023) & (USD Million)

Table 34. World Chronic Pulmonary Hypertension Drug Market Size by Application (2024-2029) & (USD Million)

Table 35. Bayer Basic Information, Area Served and Competitors

Table 36. Bayer Major Business

Table 37. Bayer Chronic Pulmonary Hypertension Drug Product and Services

Table 38. Bayer Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Bayer Recent Developments/Updates

Table 40. Bayer Competitive Strengths & Weaknesses

Table 41. Attgeno Basic Information, Area Served and Competitors

Table 42. Attgeno Major Business

Table 43. Attgeno Chronic Pulmonary Hypertension Drug Product and Services

Table 44. Attgeno Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Attgeno Recent Developments/Updates

Table 46. Attgeno Competitive Strengths & Weaknesses

Table 47. Cereno Scientific Basic Information, Area Served and Competitors

Table 48. Cereno Scientific Major Business

Table 49. Cereno Scientific Chronic Pulmonary Hypertension Drug Product and Services

Table 50. Cereno Scientific Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Cereno Scientific Recent Developments/Updates

Table 52. Cereno Scientific Competitive Strengths & Weaknesses

Table 53. Bial - Portela C S.A Basic Information, Area Served and Competitors

Table 54. Bial - Portela C S.A Major Business

Table 55. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Product and Services

Table 56. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Bial - Portela C S.A Recent Developments/Updates

Table 58. Bial - Portela C S.A Competitive Strengths & Weaknesses

Table 59. Liquidia Technologies Basic Information, Area Served and Competitors

Table 60. Liquidia Technologies Major Business

Table 61. Liquidia Technologies Chronic Pulmonary Hypertension Drug Product and Services

Table 62. Liquidia Technologies Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Liquidia Technologies Recent Developments/Updates

Table 64. Liquidia Technologies Competitive Strengths & Weaknesses

Table 65. Bellerophon Therapeutics Basic Information, Area Served and Competitors

Table 66. Bellerophon Therapeutics Major Business

Table 67. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Product and Services

Table 68. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Bellerophon Therapeutics Recent Developments/Updates

Table 70. Bellerophon Therapeutics Competitive Strengths & Weaknesses

Table 71. AbbVie Therapeutics Basic Information, Area Served and Competitors

Table 72. AbbVie Therapeutics Major Business

Table 73. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Product and

Services

Table 74. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. AbbVie Therapeutics Recent Developments/Updates

Table 76. AbbVie Therapeutics Competitive Strengths & Weaknesses

Table 77. Insmed Basic Information, Area Served and Competitors

Table 78. Insmed Major Business

Table 79. Insmed Chronic Pulmonary Hypertension Drug Product and Services

Table 80. Insmed Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Insmed Recent Developments/Updates

Table 82. Insmed Competitive Strengths & Weaknesses

Table 83. Altavant Sciences Basic Information, Area Served and Competitors

Table 84. Altavant Sciences Major Business

Table 85. Altavant Sciences Chronic Pulmonary Hypertension Drug Product and Services

Table 86. Altavant Sciences Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Altavant Sciences Recent Developments/Updates

Table 88. Altavant Sciences Competitive Strengths & Weaknesses

Table 89. Lupin Basic Information, Area Served and Competitors

Table 90. Lupin Major Business

Table 91. Lupin Chronic Pulmonary Hypertension Drug Product and Services

Table 92. Lupin Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. Lupin Recent Developments/Updates

Table 94. Lupin Competitive Strengths & Weaknesses

Table 95. Sun Pharmaceutical Basic Information, Area Served and Competitors

Table 96. Sun Pharmaceutical Major Business

Table 97. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Product and Services

Table 98. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. Sun Pharmaceutical Recent Developments/Updates

Table 100. Teva Basic Information, Area Served and Competitors

Table 101. Teva Major Business

Table 102. Teva Chronic Pulmonary Hypertension Drug Product and Services

Table 103. Teva Chronic Pulmonary Hypertension Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 104. Global Key Players of Chronic Pulmonary Hypertension Drug Upstream
(Raw Materials)

Table 105. Chronic Pulmonary Hypertension Drug Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Chronic Pulmonary Hypertension Drug Picture
- Figure 2. World Chronic Pulmonary Hypertension Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Chronic Pulmonary Hypertension Drug Total Market Size (2018-2029) & (USD Million)
- Figure 4. World Chronic Pulmonary Hypertension Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
- Figure 5. World Chronic Pulmonary Hypertension Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
- Figure 6. United States Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 7. China Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 8. Europe Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 9. Japan Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 10. South Korea Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 11. ASEAN Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 12. India Based Company Chronic Pulmonary Hypertension Drug Revenue (2018-2029) & (USD Million)
- Figure 13. Chronic Pulmonary Hypertension Drug Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)
- Figure 16. World Chronic Pulmonary Hypertension Drug Consumption Value Market Share by Region (2018-2029)
- Figure 17. United States Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)
- Figure 18. China Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)
- Figure 19. Europe Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)

Figure 23. India Chronic Pulmonary Hypertension Drug Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Chronic Pulmonary Hypertension Drug by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Chronic Pulmonary Hypertension Drug Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Chronic Pulmonary Hypertension Drug Markets in 2022

Figure 27. United States VS China: Chronic Pulmonary Hypertension Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Chronic Pulmonary Hypertension Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Chronic Pulmonary Hypertension Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Chronic Pulmonary Hypertension Drug Market Size Market Share by Type in 2022

Figure 31. Oral

Figure 32. Intravenous/Subcutaneous

Figure 33. Inhalational

Figure 34. World Chronic Pulmonary Hypertension Drug Market Size Market Share by Type (2018-2029)

Figure 35. World Chronic Pulmonary Hypertension Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World Chronic Pulmonary Hypertension Drug Market Size Market Share by Application in 2022

Figure 37. Hospital Pharmacy

Figure 38. Retail Pharmacy

Figure 39. Online Pharmacy

Figure 40. Chronic Pulmonary Hypertension Drug Industrial Chain

Figure 41. Methodology

Figure 42. Research Process and Data Source

I would like to order

Product name: Global Chronic Pulmonary Hypertension Drug Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G987B2753E04EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G987B2753E04EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

